 | • レポートコード：MRC23Q36402 • 出版社/出版日：QYResearch / 2023年3月 • レポート形態：英文、PDF、96ページ • 納品方法：Eメール（2-3日） • 産業分類：医療 |
| Single User | ￥429,200 (USD2,900) | ▷ お問い合わせ |
| Enterprise License | ￥858,400 (USD5,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートは世界の全身性アスペルギルス症/全身性カンジダ症治療市場について調査・分析し、世界の全身性アスペルギルス症/全身性カンジダ症治療市場概要、市場トレンド、主要企業別競争状況、タイプ別セグメント分析（ボリコナゾール、リポソームアムホテリシンB、全身経口アゾール、外用抗真菌剤、その他）、用途別セグメント分析（慢性肺アスペルギルス症(CPA)、アレルギー性気管支肺アスペルギルス症(ABPA)、消化管カンジダ症、泌尿生殖器カンジダ症、その他）、地域別市場規模、主要企業のプロファイルなどに関する情報を掲載しています。主要企業としては、Basilea Pharmaceutica、Astellas Pharma、Ferrer International、Pacgen Life Science、NovaDigm Therapeutics、Cidara Therapeutics、Amplyx Pharmaceuticals、Pfizer、Novartis、Sanofi、Merck、Bayer、GlaxoSmithKline、Abbott、Ciplaなどが含まれています。世界の全身性アスペルギルス症/全身性カンジダ症治療市場は、2022年にXXX米ドル、2029年にはXXX米ドルに達すると予測され、予測期間の年平均成長率はXXX％です。COVID-19とロシア・ウクライナ戦争の影響は、全身性アスペルギルス症/全身性カンジダ症治療市場規模を推定する際に考慮しました。本レポートは、全身性アスペルギルス症/全身性カンジダ症治療の世界市場を定量的・定性的な分析により包括的に提示し、読者がビジネス/成長戦略を策定し、市場競争状況を把握し、現在の市場における自社のポジションを分析し、全身性アスペルギルス症/全身性カンジダ症治療に関するビジネス上の意思決定に役立てることを目的としています。 ・全身性アスペルギルス症/全身性カンジダ症治療市場の概要 - 全身性アスペルギルス症/全身性カンジダ症治療のタイプ別セグメント - 世界の全身性アスペルギルス症/全身性カンジダ症治療市場規模：タイプ別分析（ボリコナゾール、リポソームアムホテリシンB、全身経口アゾール、外用抗真菌剤、その他） - 全身性アスペルギルス症/全身性カンジダ症治療の用途別セグメント - 世界の全身性アスペルギルス症/全身性カンジダ症治療市場規模：用途別分析（慢性肺アスペルギルス症(CPA)、アレルギー性気管支肺アスペルギルス症(ABPA)、消化管カンジダ症、泌尿生殖器カンジダ症、その他） - 世界の全身性アスペルギルス症/全身性カンジダ症治療市場規模予測（2018年-2029年） ・全身性アスペルギルス症/全身性カンジダ症治療市場の成長トレンド - 全身性アスペルギルス症/全身性カンジダ症治療の地域別市場規模（2018年-2029年） - 全身性アスペルギルス症/全身性カンジダ症治療市場ダイナミクス - 全身性アスペルギルス症/全身性カンジダ症治療の業界動向 - 全身性アスペルギルス症/全身性カンジダ症治療市場の成長ドライバ、課題、阻害要因 ・主要企業別競争状況 - 企業別市場シェア - 世界の主要企業、業界ランキング分析 - 市場への参入、M＆A動向 ・タイプ別セグメント：ボリコナゾール、リポソームアムホテリシンB、全身経口アゾール、外用抗真菌剤、その他 - 世界の全身性アスペルギルス症/全身性カンジダ症治療のタイプ別市場規模（2018年-2023年） - 世界の全身性アスペルギルス症/全身性カンジダ症治療のタイプ別市場規模（2024年-2029年） ・用途別セグメント：慢性肺アスペルギルス症(CPA)、アレルギー性気管支肺アスペルギルス症(ABPA)、消化管カンジダ症、泌尿生殖器カンジダ症、その他 - 世界の全身性アスペルギルス症/全身性カンジダ症治療の用途別市場規模（2018年-2023年） - 世界の全身性アスペルギルス症/全身性カンジダ症治療の用途別市場規模（2024年-2029年） ・全身性アスペルギルス症/全身性カンジダ症治療の地域別市場規模 - 北米の全身性アスペルギルス症/全身性カンジダ症治療市場規模（2018年-2029年） - アメリカの全身性アスペルギルス症/全身性カンジダ症治療市場規模（2018年-2029年） - ヨーロッパの全身性アスペルギルス症/全身性カンジダ症治療市場規模（2018年-2029年） - アジア太平洋の全身性アスペルギルス症/全身性カンジダ症治療市場規模（2018年-2029年） - 中国の全身性アスペルギルス症/全身性カンジダ症治療市場規模（2018年-2029年） - 日本の全身性アスペルギルス症/全身性カンジダ症治療市場規模（2018年-2029年） - 韓国の全身性アスペルギルス症/全身性カンジダ症治療市場規模（2018年-2029年） - インドの全身性アスペルギルス症/全身性カンジダ症治療市場規模（2018年-2029年） - オーストラリアの全身性アスペルギルス症/全身性カンジダ症治療市場規模（2018年-2029年） - 中南米の全身性アスペルギルス症/全身性カンジダ症治療市場規模（2018年-2029年） - 中東・アフリカの全身性アスペルギルス症/全身性カンジダ症治療市場規模（2018年-2029年） ・主要企業のプロファイル：企業情報、事業概要、売上、動向 Basilea Pharmaceutica、Astellas Pharma、Ferrer International、Pacgen Life Science、NovaDigm Therapeutics、Cidara Therapeutics、Amplyx Pharmaceuticals、Pfizer、Novartis、Sanofi、Merck、Bayer、GlaxoSmithKline、Abbott、Cipla ・アナリストの観点/結論 ・調査方法とデータソース |
Highlights
The global Systemic Aspergillosis and Systemic Candidiasis Treatment market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Systemic Aspergillosis and Systemic Candidiasis Treatment is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Systemic Aspergillosis and Systemic Candidiasis Treatment is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Systemic Aspergillosis and Systemic Candidiasis Treatment in Chronic Pulmonary Aspergillosis (CPA) is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Systemic Aspergillosis and Systemic Candidiasis Treatment include Basilea Pharmaceutica, Astellas Pharma, Ferrer International, Pacgen Life Science, NovaDigm Therapeutics, Cidara Therapeutics, Amplyx Pharmaceuticals, Pfizer and Novartis, etc. In 2022, the world’s top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Systemic Aspergillosis and Systemic Candidiasis Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Systemic Aspergillosis and Systemic Candidiasis Treatment.
The Systemic Aspergillosis and Systemic Candidiasis Treatment market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Systemic Aspergillosis and Systemic Candidiasis Treatment market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Systemic Aspergillosis and Systemic Candidiasis Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Basilea Pharmaceutica
Astellas Pharma
Ferrer International
Pacgen Life Science
NovaDigm Therapeutics
Cidara Therapeutics
Amplyx Pharmaceuticals
Pfizer
Novartis
Sanofi
Merck
Bayer
GlaxoSmithKline
Abbott
Cipla
Segment by Type
Voriconazole
Liposomal Amphotericin B
Systemic Oral Azoles
Topical Antifungal Agents
Others
Segment by Application
Chronic Pulmonary Aspergillosis (CPA)
Allergic Bronchopulmonary Aspergillosis (ABPA)
Gastrointestinal Candidiasis
Genitourinary Tract Candidiasis
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Systemic Aspergillosis and Systemic Candidiasis Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Systemic Aspergillosis and Systemic Candidiasis Treatment Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Voriconazole
1.2.3 Liposomal Amphotericin B
1.2.4 Systemic Oral Azoles
1.2.5 Topical Antifungal Agents
1.2.6 Others
1.3 Market by Application
1.3.1 Global Systemic Aspergillosis and Systemic Candidiasis Treatment Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Chronic Pulmonary Aspergillosis (CPA)
1.3.3 Allergic Bronchopulmonary Aspergillosis (ABPA)
1.3.4 Gastrointestinal Candidiasis
1.3.5 Genitourinary Tract Candidiasis
1.3.6 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Systemic Aspergillosis and Systemic Candidiasis Treatment Market Perspective (2018-2029)
2.2 Systemic Aspergillosis and Systemic Candidiasis Treatment Growth Trends by Region
2.2.1 Global Systemic Aspergillosis and Systemic Candidiasis Treatment Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Systemic Aspergillosis and Systemic Candidiasis Treatment Historic Market Size by Region (2018-2023)
2.2.3 Systemic Aspergillosis and Systemic Candidiasis Treatment Forecasted Market Size by Region (2024-2029)
2.3 Systemic Aspergillosis and Systemic Candidiasis Treatment Market Dynamics
2.3.1 Systemic Aspergillosis and Systemic Candidiasis Treatment Industry Trends
2.3.2 Systemic Aspergillosis and Systemic Candidiasis Treatment Market Drivers
2.3.3 Systemic Aspergillosis and Systemic Candidiasis Treatment Market Challenges
2.3.4 Systemic Aspergillosis and Systemic Candidiasis Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Systemic Aspergillosis and Systemic Candidiasis Treatment Players by Revenue
3.1.1 Global Top Systemic Aspergillosis and Systemic Candidiasis Treatment Players by Revenue (2018-2023)
3.1.2 Global Systemic Aspergillosis and Systemic Candidiasis Treatment Revenue Market Share by Players (2018-2023)
3.2 Global Systemic Aspergillosis and Systemic Candidiasis Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Systemic Aspergillosis and Systemic Candidiasis Treatment Revenue
3.4 Global Systemic Aspergillosis and Systemic Candidiasis Treatment Market Concentration Ratio
3.4.1 Global Systemic Aspergillosis and Systemic Candidiasis Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Systemic Aspergillosis and Systemic Candidiasis Treatment Revenue in 2022
3.5 Systemic Aspergillosis and Systemic Candidiasis Treatment Key Players Head office and Area Served
3.6 Key Players Systemic Aspergillosis and Systemic Candidiasis Treatment Product Solution and Service
3.7 Date of Enter into Systemic Aspergillosis and Systemic Candidiasis Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Systemic Aspergillosis and Systemic Candidiasis Treatment Breakdown Data by Type
4.1 Global Systemic Aspergillosis and Systemic Candidiasis Treatment Historic Market Size by Type (2018-2023)
4.2 Global Systemic Aspergillosis and Systemic Candidiasis Treatment Forecasted Market Size by Type (2024-2029)
5 Systemic Aspergillosis and Systemic Candidiasis Treatment Breakdown Data by Application
5.1 Global Systemic Aspergillosis and Systemic Candidiasis Treatment Historic Market Size by Application (2018-2023)
5.2 Global Systemic Aspergillosis and Systemic Candidiasis Treatment Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Systemic Aspergillosis and Systemic Candidiasis Treatment Market Size (2018-2029)
6.2 North America Systemic Aspergillosis and Systemic Candidiasis Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Systemic Aspergillosis and Systemic Candidiasis Treatment Market Size by Country (2018-2023)
6.4 North America Systemic Aspergillosis and Systemic Candidiasis Treatment Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Systemic Aspergillosis and Systemic Candidiasis Treatment Market Size (2018-2029)
7.2 Europe Systemic Aspergillosis and Systemic Candidiasis Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Systemic Aspergillosis and Systemic Candidiasis Treatment Market Size by Country (2018-2023)
7.4 Europe Systemic Aspergillosis and Systemic Candidiasis Treatment Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Systemic Aspergillosis and Systemic Candidiasis Treatment Market Size (2018-2029)
8.2 Asia-Pacific Systemic Aspergillosis and Systemic Candidiasis Treatment Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Systemic Aspergillosis and Systemic Candidiasis Treatment Market Size by Region (2018-2023)
8.4 Asia-Pacific Systemic Aspergillosis and Systemic Candidiasis Treatment Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Systemic Aspergillosis and Systemic Candidiasis Treatment Market Size (2018-2029)
9.2 Latin America Systemic Aspergillosis and Systemic Candidiasis Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Systemic Aspergillosis and Systemic Candidiasis Treatment Market Size by Country (2018-2023)
9.4 Latin America Systemic Aspergillosis and Systemic Candidiasis Treatment Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Systemic Aspergillosis and Systemic Candidiasis Treatment Market Size (2018-2029)
10.2 Middle East & Africa Systemic Aspergillosis and Systemic Candidiasis Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Systemic Aspergillosis and Systemic Candidiasis Treatment Market Size by Country (2018-2023)
10.4 Middle East & Africa Systemic Aspergillosis and Systemic Candidiasis Treatment Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Basilea Pharmaceutica
11.1.1 Basilea Pharmaceutica Company Detail
11.1.2 Basilea Pharmaceutica Business Overview
11.1.3 Basilea Pharmaceutica Systemic Aspergillosis and Systemic Candidiasis Treatment Introduction
11.1.4 Basilea Pharmaceutica Revenue in Systemic Aspergillosis and Systemic Candidiasis Treatment Business (2018-2023)
11.1.5 Basilea Pharmaceutica Recent Development
11.2 Astellas Pharma
11.2.1 Astellas Pharma Company Detail
11.2.2 Astellas Pharma Business Overview
11.2.3 Astellas Pharma Systemic Aspergillosis and Systemic Candidiasis Treatment Introduction
11.2.4 Astellas Pharma Revenue in Systemic Aspergillosis and Systemic Candidiasis Treatment Business (2018-2023)
11.2.5 Astellas Pharma Recent Development
11.3 Ferrer International
11.3.1 Ferrer International Company Detail
11.3.2 Ferrer International Business Overview
11.3.3 Ferrer International Systemic Aspergillosis and Systemic Candidiasis Treatment Introduction
11.3.4 Ferrer International Revenue in Systemic Aspergillosis and Systemic Candidiasis Treatment Business (2018-2023)
11.3.5 Ferrer International Recent Development
11.4 Pacgen Life Science
11.4.1 Pacgen Life Science Company Detail
11.4.2 Pacgen Life Science Business Overview
11.4.3 Pacgen Life Science Systemic Aspergillosis and Systemic Candidiasis Treatment Introduction
11.4.4 Pacgen Life Science Revenue in Systemic Aspergillosis and Systemic Candidiasis Treatment Business (2018-2023)
11.4.5 Pacgen Life Science Recent Development
11.5 NovaDigm Therapeutics
11.5.1 NovaDigm Therapeutics Company Detail
11.5.2 NovaDigm Therapeutics Business Overview
11.5.3 NovaDigm Therapeutics Systemic Aspergillosis and Systemic Candidiasis Treatment Introduction
11.5.4 NovaDigm Therapeutics Revenue in Systemic Aspergillosis and Systemic Candidiasis Treatment Business (2018-2023)
11.5.5 NovaDigm Therapeutics Recent Development
11.6 Cidara Therapeutics
11.6.1 Cidara Therapeutics Company Detail
11.6.2 Cidara Therapeutics Business Overview
11.6.3 Cidara Therapeutics Systemic Aspergillosis and Systemic Candidiasis Treatment Introduction
11.6.4 Cidara Therapeutics Revenue in Systemic Aspergillosis and Systemic Candidiasis Treatment Business (2018-2023)
11.6.5 Cidara Therapeutics Recent Development
11.7 Amplyx Pharmaceuticals
11.7.1 Amplyx Pharmaceuticals Company Detail
11.7.2 Amplyx Pharmaceuticals Business Overview
11.7.3 Amplyx Pharmaceuticals Systemic Aspergillosis and Systemic Candidiasis Treatment Introduction
11.7.4 Amplyx Pharmaceuticals Revenue in Systemic Aspergillosis and Systemic Candidiasis Treatment Business (2018-2023)
11.7.5 Amplyx Pharmaceuticals Recent Development
11.8 Pfizer
11.8.1 Pfizer Company Detail
11.8.2 Pfizer Business Overview
11.8.3 Pfizer Systemic Aspergillosis and Systemic Candidiasis Treatment Introduction
11.8.4 Pfizer Revenue in Systemic Aspergillosis and Systemic Candidiasis Treatment Business (2018-2023)
11.8.5 Pfizer Recent Development
11.9 Novartis
11.9.1 Novartis Company Detail
11.9.2 Novartis Business Overview
11.9.3 Novartis Systemic Aspergillosis and Systemic Candidiasis Treatment Introduction
11.9.4 Novartis Revenue in Systemic Aspergillosis and Systemic Candidiasis Treatment Business (2018-2023)
11.9.5 Novartis Recent Development
11.10 Sanofi
11.10.1 Sanofi Company Detail
11.10.2 Sanofi Business Overview
11.10.3 Sanofi Systemic Aspergillosis and Systemic Candidiasis Treatment Introduction
11.10.4 Sanofi Revenue in Systemic Aspergillosis and Systemic Candidiasis Treatment Business (2018-2023)
11.10.5 Sanofi Recent Development
11.11 Merck
11.11.1 Merck Company Detail
11.11.2 Merck Business Overview
11.11.3 Merck Systemic Aspergillosis and Systemic Candidiasis Treatment Introduction
11.11.4 Merck Revenue in Systemic Aspergillosis and Systemic Candidiasis Treatment Business (2018-2023)
11.11.5 Merck Recent Development
11.12 Bayer
11.12.1 Bayer Company Detail
11.12.2 Bayer Business Overview
11.12.3 Bayer Systemic Aspergillosis and Systemic Candidiasis Treatment Introduction
11.12.4 Bayer Revenue in Systemic Aspergillosis and Systemic Candidiasis Treatment Business (2018-2023)
11.12.5 Bayer Recent Development
11.13 GlaxoSmithKline
11.13.1 GlaxoSmithKline Company Detail
11.13.2 GlaxoSmithKline Business Overview
11.13.3 GlaxoSmithKline Systemic Aspergillosis and Systemic Candidiasis Treatment Introduction
11.13.4 GlaxoSmithKline Revenue in Systemic Aspergillosis and Systemic Candidiasis Treatment Business (2018-2023)
11.13.5 GlaxoSmithKline Recent Development
11.14 Abbott
11.14.1 Abbott Company Detail
11.14.2 Abbott Business Overview
11.14.3 Abbott Systemic Aspergillosis and Systemic Candidiasis Treatment Introduction
11.14.4 Abbott Revenue in Systemic Aspergillosis and Systemic Candidiasis Treatment Business (2018-2023)
11.14.5 Abbott Recent Development
11.15 Cipla
11.15.1 Cipla Company Detail
11.15.2 Cipla Business Overview
11.15.3 Cipla Systemic Aspergillosis and Systemic Candidiasis Treatment Introduction
11.15.4 Cipla Revenue in Systemic Aspergillosis and Systemic Candidiasis Treatment Business (2018-2023)
11.15.5 Cipla Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details